Edition:
United Kingdom

Fibrocell Science Inc (FCSC.OQ)

FCSC.OQ on NASDAQ Stock Exchange Capital Market

0.66USD
15 Dec 2017
Change (% chg)

$-0.04 (-5.57%)
Prev Close
$0.70
Open
$0.70
Day's High
$0.70
Day's Low
$0.66
Volume
187,916
Avg. Vol
40,903
52-wk High
$4.59
52-wk Low
$0.61

Latest Key Developments (Source: Significant Developments)

Fibrocell Science Q3 loss per share $‍0.02​
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Fibrocell Science Inc :Fibrocell reports third quarter 2017 financial results and recent highlights.Company believes that its cash and cash equivalents at September 30, 2017 will be sufficient to fund operations into Q2 of 2018​.Fibrocell expects to submit IND application for FCX-013 to FDA in Q4 of 2017, and initiate a human safety clinical trial in 2018​.Fibrocell Science Inc qtrly loss per share $‍0.02​.  Full Article

Fibrocell Science files for common stock offering of up to $23 mln
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Fibrocell Science Inc ::Fibrocell Science Inc files for common stock offering of up to $23 million - SEC filing‍​.  Full Article

Fibrocell Science says sold upto $17.6 mln in debt and other financing
Wednesday, 24 Aug 2016 

Fibrocell Science Inc : Sold upto $17.6 million in debt and other financing - SEC Filing .Total offering amount was $25 million.  Full Article

Fibrocell Science announces convertible debt and warrant financing of up to $25 mln
Tuesday, 9 Aug 2016 

Fibrocell Science Inc : Fibrocell announces convertible debt and warrant financing of up to $25 million .Fibrocell intends to use net proceeds of financing for continued clinical and pre-clinical development of its product candidates.  Full Article

Fibrocell Science announces proposed public offering
Monday, 8 Aug 2016 

Fibrocell Science Inc : Fibrocell announces proposed public offering of common stock and warrants .To use net proceeds of proposed offering for continued clinical,pre-clinical development of product candidates.  Full Article

Fibrocell Science Q2 loss per share $0.18
Thursday, 4 Aug 2016 

Fibrocell Science Inc : Fibrocell reports second quarter 2016 financial results and recent operational highlights . Q2 loss per share $0.18 .Q2 earnings per share view $-0.15 -- Thomson Reuters I/B/E/S.  Full Article

Fibrocell to wind-down azficel-T operations at its Exton, PA facility
Thursday, 30 Jun 2016 

Fibrocell Science : Says it determined on on June 29 to wind-down azficel-T operations at its Exton, PA facility and reduce workforce that supports such operations . In connection with this reduction, 24 positions are being eliminated, primarily in areas of manufacturing and quality operations . Time termination costs ranging from about $0.3 to $0.4 million . Says termination costs will be paid in third and fourth quarters of 2016 . Co also expects to incur other cash expenditures in Q3 & Q4 of 2016 related to wind-down of its azficel-T operations but cannot estimate them at this time . Says determined that its intangible assets, which represent R&D assets related to co's primary study on azficel-T, had become fully impaired . Accordingly, a non-cash impairment charge of about $3.9 million will be recorded for quarter ended June 30, 2016 Source: (http://1.usa.gov/2984m53 ) Further company coverage: [FCSC.O] (Bengaluru Newsroom: +1 646 223 8780).  Full Article

Fibrocell Science, Intrexon Corp collaborate to address diseases of the joint
Monday, 4 Jan 2016 

Intrexon Corp and Fibrocell Science Inc:Announce collaboration to address chronic inflammatory and degenerative diseases of the joint.Intrexon will receive a technology access fee of $10 million in cash and reimbursement for all research and development costs.Says agreement provides for milestone payments to Intrexon for each collaboration product of up to $30 million.Agreement provides for milestone payments to Intrexon for $22.5 million,low double-digit royalty based on net sales.  Full Article